Doing Business sheds light on how easy or difficult it is for a local entrepreneur to open and run a small to medium-size business when complying with relevant regulations. It measures and tracks changes in regulations affecting 10 areas in the life cycle of a business: starting a business, dealing with construction permits, getting electricity, registering property, getting credit, protecting investors, paying taxes, trading across borders, enforcing contracts and resolving insolvency. In a series of annual reports Doing Business presents quantitative indicators on business regulations and the protection of property rights that can be compared across 183 economies, from Afghanistan to Zimbabwe, over time. This economy profile presents the Doing Business indicators for Cambodia. To allow useful comparison, it also provides data for other selected economies (comparator economies) for each indicator. The data in this report are current as of June 1, 2011 (except for the paying taxes indicators, which cover the period January- December 2010). The data not only highlight the extent of obstacles to doing business; they also help identify the source of those obstacles, supporting policy makers in designing regulatory reform.
The Japan Fund for Poverty Reduction (JFPR) was established in May 2000 and provides direct grant assistance to the poorest and most vulnerable groups in developing member countries (DMCs) of the Asian Development Bank (ADB) while fostering long-term social and economic development. The grants target poverty reduction initiatives with the direct participation of nongovernment organizations, community groups, and civil society. In 2009, the Government of Japan and ADB expanded the scope of JFPR to include provision of support to DMCs through capacity development, policy and advisory, research and development, and project preparatory technical assistance.
Dzud is the Mongolian term for a winter weather disaster in which deep snow, severe cold, or other conditions render forage unavailable or inaccessible and lead to high livestock mortality. Dzud is a regular occurrence in Mongolia, and plays an important role in regulating livestock populations. However, dzud, especially when combined with other environmental or socio-economic stresses and changes, can have a significant impact on household well-being as well as local and national economies. This study aims to fill this gap in knowledge by conducting in-depth case studies of four communities responses to the 2009-2010 dzud to document both household-and community-level impacts and responses. The case studies use a mixed-methods approach employing qualitative and quantitative data collection and analysis techniques including interviews, focus groups, household questionnaires, photovoice and document review, and were carried out in two soums (districts) located in the forest-steppe zone of Arkhangai Aimag (province), Ikhtamir and Undur Ulaan, and two soums in the Gobi desert-steppe zone of Bayankhongor Aimag, Jinst and Bayantsagaan. The specific objectives of this study are to assess herder household and community vulnerability, adaptive capacity, and medium-term recovery and resilience from the dzud of 2010.
FONDEN (Natural Disasters Fund), Mexico's fund for natural disasters, was established in the late 1990s as a mechanism to support the rapid rehabilitation of federal and state infrastructure affected by adverse natural events. FONDEN was first created as a budget line in the Federal expenditure budget of 1996, and became operational in 1999. Funds from FONDEN could be used for the rehabilitation and reconstruction of: 1) public infrastructure at the three levels of government (federal, state, and municipal); 2) low-income housing; and 3) certain components of the natural environment. FONDEN consists of two complementary budget accounts, the FONDEN program for reconstruction and FOPREDEN program for prevention, and their respective financial accounts. The FONDEN program for reconstruction is FONDEN's primary budget account. It channels resources from the federal expenditure budget to specific reconstruction programs. The FOPREDEN program for prevention supports disaster prevention by funding activities related to risk assessment, risk reduction, and capacity building on disaster prevention. The FONDEN system is continuously evolving to integrate lessons learned over the course of years of experience.
The Japan Fund for Poverty Reduction (JFPR) was established in May 2000 and provides direct grant assistance to the poorest and most vulnerable groups in developing member countries (DMCs) of the Asian Development Bank (ADB) while fostering long-term social and economic development. The grants target poverty reduction initiatives with the direct participation of nongovernment organizations, community groups, and civil society. In 2009, the Government of Japan and ADB expanded the scope of JFPR to include provision of support to DMCs through capacity development, policy and advisory, research and development, and project preparatory technical assistance.
This report begins by documenting the Palestinian Authority's (PA's) ongoing fiscal crisis that threatens its ability to provide basic services to the population. In 2011, the PA required about US$1.5 billion dollars in budget support, of which US$200 million to cover development expenses not funded directly by donors. However, it only received about US$814 million in budget support and US$169 million in development financing, for a total of US$983 million. Ultimately, the PA can only hope to achieve fiscal sustainability through a combination of sustained private sector growth and continued internal reforms. Robust private sector growth is necessary for the PA to generate the revenues needed to sustain service delivery. Yet the private sector remains stifled as a result of Israeli restrictions on access to natural resources and markets. The West Bank has experienced a slowdown in economic growth in 2011, combined with double-digit growth in Gaza. The recovery in Gaza can be attributed to a combination of aid inflows and easing of restrictions on entry of goods from Israel-though it is important to keep in mind that the average Gaza today is worse off than s/he was back in the late nineties. The recent growth in Gaza is also driven largely by a boom in the construction sector, and Gaza infrastructure exhibits such gaps and disrepair that major investments are necessary and would generate important employment as well as future growth. The slowdown in growth in the West Bank, on the other hand, is the result of falling donor support, uncertainty caused by the PA's fiscal crisis, and lack of significant new easing of restrictions by the Government of Israel (GoI).
This document provides a summary assessment of (presented) scaled-up crediting instruments as well as existing project-based crediting schemes against a number of important general characteristics of such instruments. Its purpose is to provide insights that may inform the design and use of possible scaled-up crediting instruments. This summary assessment begins with an examination of proposals for scaled-up crediting mechanisms. It considers existing crediting instruments, that is, (i) Kyoto project mechanisms (clean development mechanism (CDM) and joint implementation (JI)); and (ii) voluntary emission reductions (VER) schemes (in the non-compliance and voluntary markets). The characteristics (or issues) covered are: (i) national and international circumstances for market-based mechanisms and how these interact; (ii) coverage and boundary setting; (iii) participation and incentives for participation; (iv) caps, baselines, and allocations (or issuance); (v) market integrity and credibility; (vi) monitoring, reporting, and verification (MRV); (vii) program authority and administration; and (viii) potential scaling up modalities.
This report summarizes the results of an assessment of the People's Republic of China (PRC) Poverty Reduction and Regional Cooperation Fund (PRC Fund), a $20 million trust fund established in 2005 by the Government of the PRC and managed by the Asian Development Bank (ADB) under its regional cooperation umbrella. The goal of PRC Fund is to accelerate poverty reduction and economic and social development in ADB developing member countries (DMCs) with tangible results. Its objective is to strengthen DMCs' capacity to reduce poverty through regional cooperation, among other means. PRC Fund was designed to operate for a span of 5 years (2005–2009), but was extended until 2011 to use up remaining uncommitted funds.
Mongolia has very significant natural resources and a large part of the population is dependent on them for their daily living. The impact of the state of the environment on the living standards of herders is obvious, but also Mongolians living in the capital Ulaanbaatar have learned that air pollution, especially in winter, and other environmental problems have a deep impact on their living standards. The Government of the Netherlands has established a Trust Fund at the World Bank to support environmental activities in Mongolia. Under this framework, the World Bank contracted the first Environment and Natural Resource Management Socio-economic Survey for Mongolia (ENRMSS) to the National Statistical Office and an international consultant, the aim of this survey is to investigate public views on environmental issues and to measure the impact of environmental problems on human welfare, measured in economic terms. The first part of section five is devoted to wildlife hunting, fishing and wild nuts and fruits gathering, while the second part of this section focuses on energy consumption. Both complete and complement the information on consumption estimated in the Socioeconomic Survey (SES). Section six presents perception and opinions of herders on issues such as the number of animals in Mongolia or the best way to manage animal movements. Finally, section seven shows results on perceptions and opinions of Mongolians regarding nature and the environment.
This report summarizes the results of an assessment of the People's Republic of China (PRC) Poverty Reduction and Regional Cooperation Fund (PRC Fund), a $20 million trust fund established in 2005 by the Government of the PRC and managed by the Asian Development Bank (ADB) under its regional cooperation umbrella. The goal of PRC Fund is to accelerate poverty reduction and economic and social development in ADB developing member countries (DMCs) with tangible results. Its objective is to strengthen DMCs' capacity to reduce poverty through regional cooperation, among other means. PRC Fund was designed to operate for a span of 5 years (2005–2009), but was extended until 2011 to use up remaining uncommitted funds.
In this paper, the authors discuss the ways in which national governments, firms, and individuals respond to policy related to food safety, environmental protection, and trade. These responses must be considered in the development of policy to ensure the best possible outcomes. It accounts for uncertainty about policy impacts and scientific knowledge and incorporates stochastic environmental factors. The authors argue use of such a model in the development of health and environmental policy can overcome capture by domestic forces opposed to trade liberalization. The effectiveness of policy, of course, is dependent upon firm and consumer response to policy. Section one describes the impacts of international transfer of species and genetic material, paying particular attention to the introduction of alien invasive species. Section two discusses issues surrounding trade in environmental amenities. Food safety and environmental regulations are reviewed in section three, along with mechanisms by which such policy can serve as a proxy for protectionists. Section four develops a risk assessment model that can be used in policy design. Section five considers the role of institutional, firm and individual behavior in the development and effectiveness of policy. Section six summarizes our analysis in offering an agenda for trade talks.
The 2005 Annual Report of the Japan Fund for Poverty Reduction1 (JFPR) is the fifth such report and covers the period from 1 January to 31 December 2005. The report describes the background and rationale, implementation progress, and achievements of the JFPR. The JFPR was established in May 2000 and provides direct grant assistance to the poorest and most vulnerable groups in developing member countries (DMCs) while fostering long-term social and economic development. The grants target initiatives in poverty reduction and foster the direct participation of non-government organizations (NGOs), community groups, and civil society.
The 2005 Annual Report of the Japan Fund for Poverty Reduction1 (JFPR) is the fifth such report and covers the period from 1 January to 31 December 2005. The report describes the background and rationale, implementation progress, and achievements of the JFPR. The JFPR was established in May 2000 and provides direct grant assistance to the poorest and most vulnerable groups in developing member countries (DMCs) while fostering long-term social and economic development. The grants target initiatives in poverty reduction and foster the direct participation of non-government organizations (NGOs), community groups, and civil society.
Only Vanderbilt University affiliated authors are listed on VUIR. For a full list of authors, access the version of record at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715680/ ; Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk associations of others remain unknown. The gene for FA type C, FANCC, has been proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. We used the Oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 95% CI 0.44-1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations. If this applies to all truncating variants in FANCC it would suggest there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit of large consortia for clarifying risk associations of rare variants. ; We thank all the individuals who took part in these studies and all the researchers, clinicians, technicians and administrative staff who have enabled this work to be carried out. We acknowledge all contributors to the COGS and OncoArray study design, chip design, genotyping, and genotype analyses. ABCFS thank Maggie Angelakos, Judi Maskiell, Gillian Dite. ABCS thanks the Blood bank Sanquin, The Netherlands. ABCTB Investigators: C.L.C., Rosemary Balleine, Robert Baxter, Stephen Braye, Jane Carpenter, Jane Dahlstrom, John Forbes, Soon Lee, Deborah Marsh, Adrienne Morey, Nirmala Pathmanathan, Rodney Scott, Allan Spigelman, Nicholas Wilcken, Desmond Yip. Samples are made available to researchers on a non-exclusive basis. The ACP study wishes to thank the participants in the Thai Breast Cancer study. Special Thanks also go to the Thai Ministry of Public Health (MOPH), doctors and nurses who helped with the data collection process. Finally, the study would like to thank Dr Prat Boonyawongviroj, the former Permanent Secretary of MOPH and Dr Pornthep Siriwanarungsan, the Department Director-General of Disease Control who have supported the study throughout. BBCS thanks Eileen Williams, Elaine Ryder-Mills, Kara Sargus. BCEES thanks Allyson Thomson, Christobel Saunders, Terry Slevin, BreastScreen Western Australia, Elizabeth Wylie, Rachel Lloyd. The BCINIS study would not have been possible without the contributions of Dr. K. Landsman, Dr. N. Gronich, Dr. A. Flugelman, Dr. W. Saliba, Dr. E. Liani, Dr. I. Cohen, Dr. S. Kalet, Dr. V. Friedman, Dr. O. Barnet of the NICCC in Haifa, and all the contributing family medicine, surgery, pathology and oncology teams in all medical institutes in Northern Israel. The BREOGAN study would not have been possible without the contributions of the following: Jose Esteban Castelao, Angel Carracedo, Victor Munoz Garzon, Alejandro Novo Dominguez, Sara Miranda Ponte, Carmen Redondo Marey, Maite Pena Fernandez, Manuel Enguix Castelo, Maria Torres, Manuel Calaza (BREOGAN), Jose Antunez, Maximo Fraga and the staff of the Department of Pathology and Biobank of the University Hospital Complex of Santiago-CHUS, Instituto de Investigacion Sanitaria de Santiago, IDIS, Xerencia de Xestion Integrada de Santiago-SERGAS; Joaquin Gonzalez-Carrero and the staff of the Department of Pathology and Biobank of University Hospital Complex of Vigo, Instituto de Investigacion Biomedica Galicia Sur, SERGAS, Vigo, Spain. BSUCH thanks Peter Bugert, Medical Faculty Mannheim. The CAMA study would like to recognize CONACyT for the financial support provided for this work and all physicians responsible for the project in the different participating hospitals: Dr. German Castelazo (IMSS, Ciudad de Mexico, DF), Dr. Sinhue Barroso Bravo (IMSS, Ciudad de Mexico, DF), Dr. Fernando Mainero Ratchelous (IMSS, Ciudad de Mexico, DF), Dr. Joaquin Zarco Mendez (ISSSTE, Ciudad de Mexico, DF), Dr. Edelmiro Perez Rodriguez (Hospital Universitario, Monterrey, Nuevo Leon), Dr. Jesus Pablo Esparza Cano (IMSS, Monterrey, Nuevo Leon), Dr. Heriberto Fabela (IMSS, Monterrey, Nuevo Leon), Dr. Fausto Hernandez Morales (ISSSTE, Veracruz, Veracruz), Dr. Pedro Coronel Brizio (CECAN SS, Xalapa, Veracruz) and Dr. Vicente A. Saldana Quiroz (IMSS, Veracruz, Veracruz). CBCS thanks study participants, co-investigators, collaborators and staff of the Canadian Breast Cancer Study, and project coordinators Agnes Lai and Celine Morissette. CCGP thanks Styliani Apostolaki, Anna Margiolaki, Georgios Nintos, Maria Perraki, Georgia Saloustrou, Georgia Sevastaki, Konstantinos Pompodakis. CGPS thanks staff and participants of the Copenhagen General Population Study. For the excellent technical assistance: Dorthe Uldall Andersen, Maria Birna Arnadottir, Anne Bank, Dorthe Kjeldgard Hansen. The Danish Cancer Biobank is acknowledged for providing infrastructure for the collection of blood samples for the cases. COLBCCC thanks all patients, the physicians Justo G. Olaya, Mauricio Tawil, Lilian Torregrosa, Elias Quintero, Sebastian Quintero, Claudia Ramirez, Jose J. Caicedo, and Jose F. Robledo, the researchers Ignacio Briceno, Fabian Gil, Angela Umana, Angela Beltran and Viviana Ariza, and the technician Michael Gilbert for their contributions and commitment to this study. Investigators from the CPSII cohort thank the participants and Study Management Group for their invaluable contributions to this research. They also acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, as well as cancer registries supported by the National Cancer Institute Surveillance Epidemiology and End Results program. CTS Investigators include Leslie Bernstein, S.L.N., James Lacey, Sophia Wang, and Huiyan Ma at the Beckman Research Institute of City of Hope, Jessica Clague DeHart at the School of Community and Global Health Claremont Graduate University, Dennis Deapen, Rich Pinder, and Eunjung Lee at the University of Southern California, Pam Horn-Ross, Christina Clarke Dur and David Nelson at the Cancer Prevention Institute of California, Peggy Reynolds, at the Department of Epidemiology and Biostatistics, University of California San Francisco, H.A-C, A.Z., and Hannah Park at the University of California Irvine, and Fred Schumacher at Case Western University. DIETCOMPLYF thanks the patients, nurses and clinical staff involved in the study. We thank the participants and the investigators of EPIC (European Prospective Investigation into Cancer and Nutrition). ESTHER thanks Hartwig Ziegler, Sonja Wolf, Volker Hermann, Christa Stegmaier, Katja Butterbach. FHRISK thanks NIHR for funding. GC-HBOC thanks Stefanie Engert, Heide Hellebrand, Sandra Krober and LIFE -Leipzig Research Centre for Civilization Diseases (Markus Loeffler, Joachim Thiery, Matthias Nuchter, Ronny Baber). The GENICA Network: Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, and University of Tubingen, Germany [H.B., W-Y.L.], German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ) [H. B.], Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - EXC 2180 -390900677, Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany [Yon-Dschun Ko, Christian Baisch], Institute of Pathology, University of Bonn, Germany [Hans-Peter Fischer], Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany [UH], Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany [Thomas Bruning, Beate Pesch, Sylvia Rabstein, Anne Lotz]; and Institute of Occupational Medicine and Maritime Medicine, University Medical Center Hamburg-Eppendorf, Germany [Volker Harth]. HABCS thanks Michael Bremer and Johann H. Karstens. HEBCS thanks Sofia Khan, Johanna Kiiski, Kristiina Aittomaki, Rainer Fagerholm, Kirsimari Aaltonen, Karl von Smitten, Irja Erkkila. HKBCS thanks Hong Kong Sanatorium and Hospital, Dr Ellen Li Charitable Foundation, The Kerry Group Kuok Foundation, National Institute of Health 1R03CA130065 and the North California Cancer Center for support. HMBCS thanks Johann H. Karstens. HUBCS thanks Shamil Gantsev. KARMA thanks the Swedish Medical Research Counsel. KBCP thanks Eija Myohanen, Helena Kemilainen. We thank all investigators of the KOHBRA (Korean Hereditary Breast Cancer) Study. LMBC thanks Gilian Peuteman, Thomas Van Brussel, EvyVanderheyden and Kathleen Corthouts. MABCS thanks Milena Jakimovska (RCGEB "Georgi D. Efremov), Emilija Lazarova (University Clinic of Radiotherapy and Oncology), Katerina Kubelka-Sabit, Mitko Karadjozov (Adzibadem-Sistina Hospital), Andrej Arsovski and Liljana Stojanovska (Re-Medika Hospital) for their contributions and commitment to this study. MARIE thanks Petra Seibold, Dieter Flesch-Janys, Judith Heinz, Nadia Obi, Alina Vrieling, Sabine Behrens, Ursula Eilber, Muhabbet Celik, Til Olchers and Stefan Nickels. MBCSG (Milan Breast Cancer Study Group): Bernard Peissel, Jacopo Azzollini, Dario Zimbalatti, Daniela Zaffaroni, Bernardo Bonanni, Mariarosaria Calvello, Davide Bondavalli, Aliana Guerrieri Gonzaga, Monica Marabelli, Irene Feroce, and the personnel of the Cogentech Cancer Genetic Test Laboratory. We thank the coordinators, the research staff and especially the MMHS participants for their continued collaboration on research studies in breast cancer. MSKCC thanks Marina Corines, Lauren Jacobs. MTLGEBCS would like to thank Martine Tranchant (CHU de QuebecUniversite Laval Research Center), Marie-France Valois, Annie Turgeon and Lea Heguy (McGill University Health Center, Royal Victoria Hospital; McGill University) for DNA extraction, sample management and skillful technical assistance. J. S. is Chair holder of the Canada Research Chair in Oncogenetics. MYBRCA thanks study participants and research staff (particularly Patsy Ng, Nurhidayu Hassan, Yoon Sook-Yee, Daphne Lee, Lee Sheau Yee, Phuah Sze Yee and Norhashimah Hassan) for their contributions and commitment to this study. The NBCS Collaborators would like to thank the Oslo Breast Cancer Research Consortium, OSBREAC (breastcancerresearch. no/osbreac/), for providing samples and phenotype data. NBHS and SBCGS thank study participants and research staff for their contributions and commitment to the studies. We would like to thank the participants and staff of the Nurses' Health Study and Nurses' Health Study II for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. The authors assume full responsibility for analyses and interpretation of these data. OFBCR thanks Teresa Selander, Nayana Weerasooriya. ORIGO thanks E. Krol-Warmerdam, and J. Blom for patient accrual, administering questionnaires, and managing clinical information. The ORIGO survival data were retrieved from the Leiden hospital-based cancer registry system (ONCDOC) with the help of Dr. J. Molenaar. PBCS thanks Louise Brinton, Mark Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Witold Zatonski, Pei Chao, Michael Stagner. The ethical approval for the POSH study is MREC/00/6/69, UKCRN ID: 1137. We thank staff in the Experimental Cancer Medicine Centre (ECMC) supported Faculty of Medicine Tissue Bank and the Faculty of Medicine DNA Banking resource. PREFACE thanks Sonja Oeser and Silke Landrith. PROCAS thanks NIHR for funding. RBCS thanks Petra Bos, Jannet Blom, Ellen Crepin, Elisabeth Huijskens, Anja Kromwijk-Nieuwlaat, Annette Heemskerk, the Erasmus MC Family Cancer Clinic. We thank the SEARCH and EPIC teams. SGBCC thanks the participants and research coordinator Ms Tan Siew Li. SKKDKFZS thanks all study participants, clinicians, family doctors, researchers and technicians for their contributions and commitment to this study. We thank the SUCCESS Study teams in Munich, Duessldorf, Erlangen and Ulm. SZBCS thanks Ewa Putresza. UCIBCS thanks Irene Masunaka. UKBGS thanks Breast Cancer Now and the Institute of Cancer Research for support and funding of the Breakthrough Generations Study, and the study participants, study staff, and the doctors, nurses and other health care providers and health information sources who have contributed to the study. We acknowledge NHS funding to the Royal Marsden/ICR NIHR Biomedical Research Centre. BCAC is funded by Cancer Research UK [C1287/A16563, C1287/A10118], the European Union's Horizon 2020 Research and Innovation Programme (grant numbers 634935 and 633784 for BRIDGES and B-CAST respectively), and by the European Community's Seventh Framework Programme under grant agreement number 223175 (Grant Number HEALTH-F2-2009-223175) (COGS). The EU Horizon 2020 Research and Innovation Programme funding source had no role in study design, data collection, data analysis, data interpretation or writing of the report. Genotyping of the OncoArray was funded by the NIH Grant U19 CA148065, and Cancer UK Grant C1287/A16563 and the PERSPECTIVE project supported by the Government of Canada through Genome Canada and the Canadian Institutes of Health Research (grant GPH-129344) and, the Ministere de l'Economie, Science et Innovation du Quebec through Genome Quebec and the PSR-SIIRI-701 grant, and the Quebec Breast Cancer Foundation. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement No. 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 -the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, and Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. The DRIVE Consortium was funded by U19 CA148065. The Australian Breast Cancer Family Study (ABCFS), BCFR-NY, BCFR-PA, BCFR-UTAH, the Northern California Breast Cancer Family Registry (NCBCFR) and Ontario Familial Breast Cancer Registry (OFBCR) were supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. J.L.H. is a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellow. M.C.S. is a NHMRC Senior Research Fellow. The ABCS study was supported by the Dutch Cancer Society [grants NKI 2007-3839; 2009 4363]. The Australian Breast Cancer Tissue Bank (ABCTB) was supported by the National Health and Medical Research Council of Australia, The Cancer Institute NSW and the National Breast Cancer Foundation. C.L.C is a NHMRC Principal Research Fellow. The ACP study is funded by the Breast Cancer Research Trust, UK and KM and AL are supported by the NIHR Manchester Biomedical Research Centre and by the ICEP ("This work was also supported by CRUK [grant number C18281/A19169]"). The AHS study is supported by the intramural research program of the National Institutes of Health, the National Cancer Institute (grant number Z01-CP010119), and the National Institute of Environmental Health Sciences (grant number Z01-ES049030). The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. The BBCS is funded by Cancer Research UK and Breast Cancer Now and acknowledges NHS funding to the NIHR Biomedical Research Centre, and the National Cancer Research Network (NCRN). The BCEES was funded by the National Health and Medical Research Council, Australia and the Cancer Council Western Australia and acknowledges funding from the National Breast Cancer Foundation (J.S.). The BREast Oncology GAlician Network (BREOGAN) is funded by Accion Estrategica de Salud del Instituto de Salud Carlos III FIS PI12/02125/Cofinanciado FEDER; Accion Estrategica de Salud del Instituto de Salud Carlos III FIS Intrasalud (PI13/01136); Programa Grupos Emergentes, Cancer Genetics Unit, Instituto de Investigacion Biomedica Galicia Sur. Xerencia de Xestion Integrada de Vigo-SERGAS, Instituto de Salud Carlos III, Spain; Grant 10CSA012E, Conselleria de Industria Programa Sectorial de Investigacion Aplicada, PEME I+ D e I + D Suma del Plan Gallego de Investigacion, Desarrollo e Innovacion Tecnologica de la Conselleria de Industria de la Xunta de Galicia, Spain; Grant EC11-192. Fomento de la Investigacion Clinica Independiente, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain; and Grant FEDER-Innterconecta. Ministerio de Economia y Competitividad, Xunta de Galicia, Spain. The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the German Cancer Research Center (DKFZ). The CAMA study was funded by Consejo Nacional de Ciencia y Tecnologia (CONACyT) (SALUD-2002-C01-7462). Sample collection and processing was funded in part by grants from the National Cancer Institute (NCI R01CA120120 and K24CA169004). CBCS is funded by the Canadian Cancer Society (grant #313404) and the Canadian Institutes of Health Research. CCGP is supported by funding from the University of Crete. The CECILE study was supported by Fondation de France, Institut National du Cancer (INCa), Ligue Nationale contre le Cancer, Agence Nationale de Securite Sanitaire, de l'Alimentation, de l'Environnement et du Travail (ANSES), Agence Nationale de la Recherche (ANR). The CGPS was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council, and Herlev and Gentofte Hospital. COLBCCC is supported by the German Cancer Research Center (DKFZ), Heidelberg, Germany. Diana Torres was in part supported by a postdoctoral fellowship from the Alexander von Humboldt Foundation. The American Cancer Society funds the creation, maintenance, and updating of the CPSII cohort. The CTS was supported by the California Breast Cancer Act of 1993, the California Breast Cancer Research Fund (contract 97-10500) and the National Institutes of Health (R01 CA77398, K05 CA136967, UM1 CA164917, and U01 CA199277). Collection of cancer incidence data was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. HAC receives support from the Lon V Smith Foundation (LVS39420). The University of Westminster curates the DietCompLyf database funded by the charity Against Breast Cancer (Registered Charity No. 1121258) and the NCRN. The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by: Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, Institut National de la Sante et de la Recherche Medicale (INSERM) (France); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF) (Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada, PI13/01162 to EPIC-Murcia, Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). The ESTHER study was supported by a grant from the Baden Wurttemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). FHRISK is funded from NIHR grant PGfAR 0707-10031. DGE is supported by the all Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007). The GC-HBOC (German Consortium of Hereditary Breast and Ovarian Cancer) is supported by the German Cancer Aid (grant no 110837, coordinator: R.K.S., Cologne). This work was also funded by the European Regional Development Fund and Free State of Saxony, Germany (LIFE - Leipzig Research Centre for Civilization Diseases, project numbers 713-241202, 713-241202, 14505/2470, 14575/2470). The GENICA was funded by the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114, the Robert Bosch Foundation, Stuttgart, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, as well as the Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany. The GEPARSIXTO study was conducted by the German Breast Group GmbH. The GESBC was supported by the Deutsche Krebshilfe e.V. [70492] and the German Cancer Research Center (DKFZ). The HABCS study was supported by the Claudia von Schilling Foundation for Breast Cancer Research, by the Lower Saxonian Cancer Society, by the Friends of Hannover Medical School and by the Rudolf Bartling Foundation. The HEBCS was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society, and the Sigrid Juselius Foundation. The HERPACC was supported by MEXT Kakenhi (No. 170150181 and 26253041) from the Ministry of Education, Science, Sports, Culture and Technology of Japan, by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from Ministry Health, Labour and Welfare of Japan, by Health and Labour Sciences Research Grants for Research on Applying Health Technology from Ministry Health, Labour and Welfare of Japan, by National Cancer Center Research and Development Fund, and "Practical Research for Innovative Cancer Control (15ck0106177h0001)" from Japan Agency for Medical Research and development, AMED, and Cancer Bio Bank Aichi. The HMBCS and HUBCS were funded by the German Research Foundation (Do761/10-1) and by the Rudolf Bartling Foundation. The HUBCS was further supported by a grant from the German Federal Ministry of Research and Education (RUS08/017), and by the Russian Foundation for Basic Research and the Federal Agency for Scientific Organizations for support the Bioresource collections and RFBR grants 14-04-97088, 17-29-06014 and 17-44-020498. Financial support for KARBAC was provided through the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, the Swedish Cancer Society, The Gustav V Jubilee foundation and Bert von Kantzows foundation. The KARMA study was supported by Marit and Hans Rausings Initiative Against Breast Cancer. The KBCP was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, Cancer Fund of North Savo, the Finnish Cancer Organizations, and by the strategic funding of the University of Eastern Finland. The KOHBRA study was partially supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), and the National R&D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea (HI16C1127; 1020350; 1420190). LMBC is supported by the 'Stichting tegen Kanker'. DL is supported by the FWO. The MABCS study is funded by the Research Centre for Genetic Engineering and Biotechnology "Georgi D. Efremov" and supported by the German Academic Exchange Program, DAAD. The MARIE study was supported by the Deutsche Krebshilfe e. V. [70-2892-BR I, 106332, 108253, 108419, 110826, 110828], the Hamburg Cancer Society, the German Cancer Research Center (DKFZ) and the Federal Ministry of Education and Research (BMBF) Germany [01KH0402]. MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds from the Italian citizens who allocated the 5/1000 share of their tax payment in support of the Fondazione IRCCS Istituto Nazionale Tumori, according to Italian laws (INT-Institutional strategic projects "5 x 1000"). The MCBCS was supported by the NIH grants CA192393, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057 and 396414, and by infrastructure provided by Cancer Council Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW), including the National Death Index and the Australian Cancer Database. The MEC was supported by NIH grants CA63464, CA54281, CA098758, CA132839 and CA164973. The MISS study is supported by funding from ERC-2011-294576 Advanced grant, Swedish Cancer Society, Swedish Research Council, Local hospital funds, Berta Kamprad Foundation, Gunnar Nilsson. The MMHS study was supported by NIH grants CA97396, CA128931, CA116201, CA140286 and CA177150. MSKCC is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative. The work of MTLGEBCS was supported by the Quebec Breast Cancer Foundation, the Canadian Institutes of Health Research for the " CIHR Team in Familial Risks of Breast Cancer" program -grant #CRN-87521 and the Ministry of Economic Development, Innovation and Export Trade - grant #PSR-SIIRI-701. MYBRCA is funded by research grants from the Malaysian Ministry of Higher Education (UM. C/HlR/MOHE/06) and Cancer Research Malaysia. MYMAMMO is supported by research grants from Yayasan Sime Darby LPGA Tournament and Malaysian Ministry of Higher Education (RP046B-15HTM). The NBCS has received funding from the K.G. Jebsen Centre for Breast Cancer Research; the Research Council of Norway grant 193387/V50 (to A-L Borresen-Dale and V.N.K.) and grant 193387/H10 (to A-L Borresen-Dale and V. N. K.), South Eastern Norway Health Authority (grant 39346 to A-L Borresen-Dale) and the Norwegian Cancer Society (to A-L Borresen-Dale and V. N. K.). The NBHS was supported by NIH grant R01CA100374. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The Carolina Breast Cancer Study (NCBCS) was funded by Komen Foundation, the National Cancer Institute (National Cancer Institute CA058223, U54 CA156733, U01 CA179715), and the North Carolina University Cancer Research Fund. The NGOBCS was supported by the National Cancer Center Research and Development Fund. The NHS was supported by NIH grants P01 CA87969, UM1 CA186107, and U19 CA148065. The NHS2 was supported by NIH grants UM1 CA176726 and U19 CA148065. The ORIGO study was supported by the Dutch Cancer Society (RUL 1997-1505) and the Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL CP16). The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. Genotyping for PLCO was supported by the Intramural Research Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and Genetics. The PLCO is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and supported by contracts from the Division of Cancer Prevention, National Cancer Institute, National Institutes of Health. The POSH study is funded by Cancer Research UK (grants C1275/A11699, C1275/C22524, C1275/A19187, C1275/A15956 and Breast Cancer Campaign 2010PR62, 2013PR044. PROCAS is funded from NIHR grant PGfAR 0707-10031. The RBCS was funded by the Dutch Cancer Society (DDHK 2004-3124, DDHK 2009-4318). The SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SBCGS was supported primarily by NIH grants R01CA64277, R01CA148667, UMCA182910, and R37CA70867. Biological sample preparation was conducted the Survey and Biospecimen Shared Resource, which is supported by P30 CA68485. The scientific development and funding of this project were, in part, supported by the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network U19 CA148065. SEARCH is funded by Cancer Research UK [C490/A10124, C490/A16561] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge. The University of Cambridge has received salary support for PDPP from the NHS in the East of England through the Clinical Academic Reserve. SEBCS was supported by the BRL (Basic Research Laboratory) program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012-0000347). SGBCC is funded by the NUS start-up Grant, National University Cancer Institute Singapore (NCIS) Centre Grant and the NMRC Clinician Scientist Award. Additional controls were recruited by the Singapore Consortium of Cohort StudiesMulti-ethnic cohort (SCCS-MEC), which was funded by the Biomedical Research Council, grant number: 05/1/21/19/425. The Sister Study (SISTER) is supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES049033). The Two Sister Study (2SISTER) was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01-ES044005 and Z01-ES102245), and, also by a grant from Susan G. Komen for the Cure, grant FAS0703856. SKKDKFZS is supported by the DKFZ. The SMC is funded by the Swedish Cancer Foundation. The SZBCS was supported by Grant PBZ_KBN_122/P05/2004. The TNBCC was supported by: a Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a grant from the Breast Cancer Research Foundation, a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ohio State University Comprehensive Cancer Center. The TWBCS is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan. The UCIBCS component of this research was supported by the NIH [CA58860, CA92044] and the Lon V Smith Foundation [LVS39420]. The UKBGS is funded by Breast Cancer Now and the Institute of Cancer Research (ICR), London. ICR acknowledges NHS funding to the NIHR Biomedical Research Centre. The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. The USRT Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The WAABCS study was supported by grants from the National Cancer Institute of the National Institutes of Health (R01 CA89085 and P50 CA125183 and the D43 TW009112 grant), Susan G. Komen (SAC110026), the Dr. Ralph and Marian Falk Medical Research Trust, and the Avon Foundation for Women.
v. 750. V -- Vallejo L -- v. 751. Vallejo M -- Vans -- v. 752. Vänt -- Vážn -- v. 753. Vazo -- Venezuela Com -- v. 754. Venezuela Con -- Vereim -- v. 755. Verein -- Vers L -- v. 756. Vers M -- Victor M -- v. 757. Victor O -- Vigd -- v. 758. Vige -- Vinea -- v. 759. Vineb -- Vision R -- v. 760. Vision S -- Voice C -- v. 761. Voice D -- Voso -- v. 762. Vosp -- Vz -- v. 763. W -- Wagner, Richard A -- v. 764. Wagner, Richard B -- Walker, William F -- v. 765. Walker, William G -- Walz -- v. 766. Wam -- Ward A -- v. 767. Ward B -- Warsh -- v. 768. Warsi -- Waso -- v. 769. Wasp -- Water Supply Engineering B -- v. 770. Water Supply Engineering C -- Weak -- v. 771. Weal -- Wedk -- v. 772. Wedl -- Welc -- v. 773. Weld -- Wenzel R -- v. 774. Wenzel S -- West Virginia I -- v. 775. West Virginia J -- Whare -- v. 776. Wharf -- White E -- v. 777. White F -- Whittier L -- v. 778. Whittier M -- Wijg -- v. 779. Wijh -- William B -- v. 780. William C -- Willis S -- v. 781. Willis T -- Wimh -- v. 782. Wimi -- Winters G -- v. 783. Winters H -- Wit and Humor, American R -- v. 784. Wit and Humor, American S -- Woh -- v. 785. Woi -- Woman-Employment-U.S.T -- v. 786. Woman-Employment-U.S.U -- Wood G -- v. 787. Wood H -- Woold -- v. 788. Woole -- World Politics, 1919- T -- v. 789. World Politics, 1919- U -- World War, 1939-1945 EC -- v. 790. World War, 1939-1945 ED -- World War, 1939-1945 Ph -- v. 791. World War, 1939-1945 Pi -- World War, 1939-1945 Regional C -- v. 792. World War, 1939-1945 Regional D -- Wright G -- v. 793. Wright H -- Wz -- v. 794. X -- Yeast V -- v. 795. Yeast W -- Young C -- v. 796. Young D -- Yz -- v. 797. Z -- Zehn J -- v. 798. Zehn K -- Zimmerman C -- v. 799. Zimmerman D -- Zoology A -- v. 800. Zoology B -- Zy. ; v. 730. U -- Underdeveloped Areas A -- v. 731. Underdeveloped Areas B -- Union of South Africa So -- v. 732. Union of South Africa Sp -- United States Adu -- v. 733. United States Adv -- United States Army R -- v. 734. United States Army S -- United States Commerce C -- v. 735. United States Commerce D -- United States Division S -- v. 736. United States Division T -- United States Foreign Relations R -- v. 737. United States Relations S -- United States Historic -- v. 738. United States History -- United States History-Revolution-Poetry S -- v. 739. United States History-Revolution-Poetry T -- United States History-Civil War-Military-Regimental History L -- v. 740. United States History-Civil War-Military-Regimental History M -- United States History-Yearbooks -- v. 741. United States Ho -- United States Justice Department Ac -- v. 742. United States Justice Department Ad -- United States National Aeronautic and Space Administration R -- v. 743. United States National Aeronautic and Space Administration S -- United States Politics, 1865-1897 J -- v. 744. United States Politics, 1865-1897 K -- United States Rac -- v. 745. United States Rad -- United States State Department P -- v. 746. United States State Department Q -- United States War Information Office A -- v. 747. United States War Information Office B -- Université S -- v. 748. Université T -- Urban O -- v. 749. Urban P -- Uz. ; v. 703. T -- Tall -- v. 704. Talm -- Tariff I -- v. 705. Tariff J -- Taxation-Jurisprudence F -- v. 706. Taxation-Jurisprudence G -- Taylor Jer -- v. 707. Taylor Jes -- Tecn -- v. 708. Teco -- Television C -- v. 709. Television D -- Tena -- v. 710. Tenb -- Tess -- v. 711. Test -- Textile Machinery S -- v. 712. Textile Machinery T -- Their -- v. 713. Theis -- Thern -- v. 714. Thero -- Thomas V -- v. 715. Thomas W -- Thorpe B -- v. 716. Thorpe C -- Tidev -- v. 717. Tidew -- Tires -- v. 718. Tiret -- Tokio G -- v. 719. Tokio H -- Torl -- v. 720. Torm -- Towards E -- v. 721. Towards F -- Trade Unions G -- v. 722. Trade Unions H -- Transcendentalism B -- v. 723. Transcendentalism C -- Treason-Trials H -- v. 724. Treason-Trials I -- Trial -- v. 725. Triam -- Trotzky, Lev G -- v. 726. Trotzky, Lev H -- Tube R -- v. 727. Tube S -- Turin C -- v. 728. Turin D -- Tuw -- v. 729. Tux -- Tz. ; v. 636. S -- Safe -- v. 637. Saff -- Saint Louis G -- v. 638. Saint Louis H -- Saler -- v. 639. Sales -- Salvation Army R -- v. 640. Salvation Army S -- Sanchez L -- v. 641. Sanchez M -- Sans -- v. 642. Sant -- Sarl -- v. 643. Sarm -- Savar -- v. 644. Savas -- Schaa -- v. 645. Schab -- Schid -- v. 646. Schie -- Schmidt B -- v. 647. Schmidt C -- Scholl S -- v. 648. Scholl T -- Schopf E -- v. 649. Schopf F -- Schulze F -- v. 650. Schulze G -- Science Col -- v. 651. Science Com -- Scoa -- v. 652. Scob -- Scott -- v. 653. Scotu -- Seals and Seal Fisheries C -- v. 654. Seals and Seal Fisheries D -- Sedl -- v. 655. Sedm -- Sell -- v. 656. Selm -- Sericulture A -- v. 657. Sericulture B -- Sever G -- v. 658. Sever H -- Shakers L -- v. 659. Shakers M -- Shakespeare A -- v. 660. Shakespeare B -- Sheldon S -- v. 661. Sheldon T -- Shipping G -- v. 662. Shipping H -- Shórn -- v. 663. Shoro -- Shrub -- v. 664. Shruc -- Sigg -- v. 665. Sigh -- Simek -- v. 666. Simel -- Singing Q -- v. 667. Singing R -- Skinner B -- v. 668. Skinner C -- Slavs B -- v. 669. Slavs C -- Smith A -- v. 670. Smith B -- Smith, William A -- v. 671. Smith, William B -- Social D -- v. 672. Social E -- Socialism, 1923-1933 H -- v. 673. Socialism, 1923-1933 I -- Societe Al -- v. 674. Société AM -- Societies R -- v. 675. Societies S -- Sociology T -- v. 676. Sociology U -- Solís -- v. 677. Solit -- Sonh -- v. 678. Soni -- Sousa A -- v. 679. Sousa B -- Southgate V -- v. 680. Southgate W -- Spain-Foreign Relations F -- v. 681. Spain-Foreign Relations G -- Spanish America-History-to 1600 -- v. 682. Spanish America-History-after 1600 -- Speech O -- v. 683. Speech P -- Spirit F -- v. 684. Spirit G -- Spuc -- v. 685. Spud -- Stage-France O -- v. 686. Stage-France P -- Stanford R -- v. 687. Stanford S -- Statement F -- v. 688. Statement G -- Sted -- v. 689. Stee -- Stel -- v. 690. Stem -- Stevenson I -- v. 691. Stevenson J -- Stockholders F -- v. 692. Stockholders G -- Storg -- v. 693. Storh -- Straus D -- v. 694. Straus E -- Struc -- v. 695. Strud -- Stuer -- v. 696. Stues -- Sueb -- v. 697. Suec -- Summ -- v. 698. Sumn -- Surim -- v. 699. Surin -- Swan H -- v. 700. Swan I -- Swey -- v. 701. Swez -- Symbolism in Architecture R -- v. 702. Symbolism in Architecture S -- Sz. ; v. 603. Q -- Quek -- v. 604. Quel -- Qw -- v. 605. R -- Radio in Politics B -- v. 606. Radio in Politics C -- Railways Ab -- v. 607. Railways Ac -- Railways D -- v. 608. Railways E -- Rak -- v. 609. Ral -- Rape -- v. 610. Rapf -- Raymond V -- v. 611. Raymond W -- Recei -- v. 612. Récéj -- Reed V -- v. 613. Reed W -- Régim -- v. 614. Regin -- Reiner I -- v. 615. Reiner J -- Religion I -- v. 616. Religion J -- Rentm -- v. 617. Rentn -- Retail Trade R -- v. 618. Retail Trade S -- Revue S -- v. 619. Revue T -- Rhodesia, Northern L -- v. 620. Rhodesia, Northern M -- Richl -- v. 621. Richm -- Rihs -- v. 622. Riht -- Ritter C -- v. 623. Ritter D -- Roads-U.S.M -- v. 624. Roads-U.S.N -- Robinson J -- v. 625. Robinson K -- Rodrigues G -- v. 626. Rodrigues H -- Rolfe F -- v. 627. Rolfe G -- Rome (City)-P -- v. 628. Rome (City)-Q -- Rord -- v. 629. Rore -- Ross C -- v. 630. Ross D -- Rousseau L -- v. 631. Rousseau M -- Roźd -- v. 632. Roze -- Rul -- v. 633. Rum -- Russia Ar -- v. 634. Russia As -- Russia-Social Conditions, 1917 K -- v. 635. Russia-Social Conditions, 1917 L -- Rz. ; v. 548. P -- Pagg -- v. 549. Pagh -- Paintings-Collections R -- v. 550. Paintings-Collections S -- Paleography L -- v. 551. Paleography M -- Palmer K -- v. 552. Palmer L -- Pann -- v. 553. Pano -- Pap -- v. 554. Paq -- Paris E -- v. 555. Paris F -- Parkh -- v. 556. Parki -- Parties, Political D -- v. 557. Parties, Political E -- Patd -- v. 558. Paté -- Paul J -- v. 559. Paul K -- Pearce C -- v. 560. Pearce D -- Pei -- v. 561. Pej -- Pennsylvania F -- v. 562. Pennsylvania G -- Pén [i.e. Pénz] -- v. 563. Peo -- Periodicals C -- v. 564. Periodicals D -- Periodicals-U.S.I -- v. 565. Periodicals-U.S.J -- Persia C -- v. 566. Persia D -- Peru -- v. 567. Perv -- Petri R -- v. 568. Petri S -- Pfeiffer E -- v. 569. Pfeiffer F -- Philip G -- v. 570. Philip H -- Philology S -- v. 571. Philology T -- Phok -- v. 572. Phol -- Phrom -- v. 573. Phron -- Picb -- v. 574. Picc -- Pik -- v. 575. Pil -- Pioneer Life-U.S.V -- v. 576. Pioneer Life-U.S.W -- Pittsburgh S -- v. 577. Pittsburgh T -- Plas -- v. 578. Plat -- Plup -- v. 579. Pluq -- Poetry, American A -- v. 580. Poetry, American B -- Poetry, American Wis -- v. 581. Poetry, American, Wit -- Poetry, Dutch S -- v. 582. Poetry, Dutch T -- Poetry, English, Hist. & Crit., 20th Cent. C -- v. 583. Poetry, English, Hist. & Crit., 20th Cent. D -- Poetry, Hungarian A -- v. 584. Poetry, Hungarian, B -- Poetry, Spanish P -- v. 585. Poetry, Spanish Q -- Poland F -- v. 586. Poland G -- Polish Literature, Hist. & Crit. O -- v. 587. Polish Literature, Hist. & Crit. P -- Polska Akademja Umiejetnosci A -- v. 588. Polska Akademja Umiejetnosci B -- Popar -- v. 589. Popas -- Portrait S -- v. 590. Portrait T -- Postage Stamps R -- v. 591. Postage Stamps S -- Poula -- v. 592. Poulb -- Pram -- v. 593. Pran -- Press, Liberty of H -- v. 594. Press, Liberty of I -- Prier -- v. 595. Pries -- Printing G -- v. 596. Printing H -- Privies N -- v. 597. Privies O -- Proj -- v. 598. Prok -- Protection V -- v. 599. Protection W -- Prussia-History-Frederick II C -- v. 600. Prussia-History-Frederick II D -- Psyk -- v. 601. Psyl -- Puli -- v. 602. Pulj -- Pyz. ; v. 509. N -- Nan -- v. 510. Nao -- Nash -- v. 511. Nasi -- National C -- v. 512. National D -- National Sh -- v. 513. National Si -- Natural History R -- v. 514. Natural History S -- Naval E -- v. 515. Naval F -- Navy R -- v. 516. Navy S -- Ned -- v. 517. Nee -- Neh -- v. 518. Nei -- Netherlands (Kingdom, 1815- ) O -- v. 519. Netherlands (Kingdom, 1815- ) P -- Neud -- v. 520. Neue -- New England D -- v. 521. New England E -- New K -- v. 522. New L -- New York (city) B -- v. 523. New York (city) C -- New York (city) L -- v. 524. New York (city) M -- New York N -- v. 525. New York O -- New York (state) H -- v. 526. New York (state) I -- New Zealand C -- v. 527. New Zealand D -- Newspapers E -- v. 528. Newspapers F -- Nicol -- v. 529. Nicom -- Ninn -- v. 530. Nino -- Nole -- v. 531. Nolf -- North Am -- v. 532. North An -- Northwestern O -- v. 533. Northwestern P -- Noth -- v. 534. Notti -- Numismatics C -- v. 535. Numismatics D -- Nz -- v. 536. O -- Occupations C -- v. 537. Occupations D -- Oese -- v. 538. Oesf -- Ohio H -- v. 539. Ohio I -- Old L -- v. 540. Old M -- Omaha R -- v. 541. Omaha S -- Oor -- v. 542. Oos -- Oratory R -- v. 543. Oratory S -- Organic R -- v. 544. Organic S -- Orrego L -- v. 545. Orrego M -- Ostl -- v. 546. Ostm -- Outs -- v. 547. Outt -- Oz. ; v. 450. M -- Mccol -- v. 451. Mccom -- Mcgrad -- v. 452. Mcgrae -- Mackenzie G -- v. 453. Mackenzie H -- Macq -- v. 454. Macr -- Maga -- v. 455. Magb -- Maic -- v. 456. Maid -- Malat -- v. 457. Malau -- Maml -- v. 458. Mamm -- Mana -- v. 459. Manb -- Mannk -- v. 460. Mannl -- Many -- v. 461. Manz -- Marc -- v. 462. Mard -- Maris -- v. 463. Marit -- Marriage F -- v. 464. Marriage G -- Martens E -- v. 465. Martens F -- Martr -- v. 466. Marts -- Masc -- v. 467. Masd -- Massachusetts I -- v. 468. Massachusetts J -- Mathematics K -- v. 469. Mathematics L -- Matthews D -- v. 470. Matthews E -- Max -- v. 471. May -- Meb -- v. 472. Mec -- Medic -- v. 473. Medid -- Mej -- v. 474. Mek -- Memory R -- v. 475. Memory S -- Meq -- v. 476. Mer -- Merv -- v. 477. Merw -- Meteorology C -- v. 478. Meteorology D -- Metropolitan M -- v. 479. Metropolitan N -- Mexico G -- v. 480. Mexico H -- Meyk -- v. 481. Meyl -- Mich -- v. 482. Mici -- Mikn -- v. 483. Mikó -- Military L -- v. 484. Military M -- Milla -- v. 485. Millb -- Milton L -- v. 486. Milton M -- Mines and Mining G -- v. 487. Mines and Mining H -- Mirac -- v. 488. Mirad -- Missions, Foreign E -- v. 489. Missions, Foreign F -- Mitb -- v. 490. Mitc -- Modn -- v. 491. Modo -- Moll -- v. 492. Molm -- Money F -- v. 493. Money G -- Monof -- v. 494. Monog -- Monteiro L -- v. 495. Monteiro M -- Mónu -- v. 496. Monv -- Mord -- v. 497. More -- Morl -- v. 498. Morm -- Morse E -- v. 499. Morse F -- Motd -- v. 500. Mote -- Mountaineering M -- v. 501. Mountaineering N -- Moving Pictures R -- v. 502. Moving Pictures S -- Mufs -- v. 503. Muft -- Municipal C -- v. 504. Municipal D -- Murk -- v. 505. Murl -- Music B -- v. 506. Music C -- Music T -- v. 507. Music U -- Mutt -- v. 508. Mutu -- Mz. ; v. 414. L -- Labor G -- v. 415. Labor H -- Labour Party, Gt. Br. D -- v. 416. Labour Party, Gt. Br. E -- Lagd -- v. 417. Lage -- Lamm -- v. 418. Lamn -- Land, Public-U.S.N -- v. 419. Land, Public-U.S.O -- Lang O -- v. 420. Lang P -- Lapk -- v. 421. Lapl -- Latg -- v. 422. Lath -- Latth -- v. 423. Latti -- Law S -- v. 424. Law T -- Law, Maritime A -- v. 425. Law, Maritime B -- Leadh -- v. 426. Leadi -- Lebn -- v. 427. Lebo -- Lefk -- v. 428. Lefl -- Lehm -- v. 429. Lehn -- Lenc -- v. 430. Lend -- Leroy E -- v. 431. Leroy F -- Letters E -- v. 432. Letters F -- Levn -- v. 433. Levo -- Liberalism K -- v. 434. Liberalism L -- Libraries (Place) N -- v. 435. Libraries (Place) O -- Lich -- v. 436. Lici -- Lighthouses H -- v. 437. Lighthouses I -- Lincoln A -- v. 438. Lincoln B -- Lior -- v. 439. Lios -- Literature P -- v. 440. Literature Q -- Living Expenses G -- v. 441. Living Expenses H -- Locomotives A -- v. 442. Locomotives B -- Loll -- v. 443. Lolm -- London U -- v. 444. London V -- Lord R -- v. 445. Lord S -- Louis XVI -- v. 446. Louis XVII -- Lowe S -- v. 447. Lowe T -- Ludwig O -- v. 448. Ludwig P -- Lutg -- v. 449. Luth -- Lz. ; v. 363. I -- Idn -- v. 364. Ido -- Illumination of Books and Manuscripts S -- v. 365. Illumination of Books and Manuscripts T -- Impos -- v. 366. Impot -- Independence D -- v. 367. Independence E -- India, History E -- v. 368. India, History F -- Indians, Central America, Tribes L -- v. 369. Indians, Central America, Tribes M -- Indians, North America S -- v. 370. Indians, North America T -- Indib -- v. 371. Indić -- Industrial Arts (Place) E -- v. 372. Industrial Arts (Place) F -- Industries (Place) U -- v. 373. Industries (Place) V -- Inl -- v. 374. Inm -- Institut M -- v. 375. Institut N -- Insurance I -- v. 376. Insurance J -- Intellectuals (Place) F -- v. 377. Intellectuals (Place) G -- International Ch -- v. 378. International Ci -- International LaC -- v. 379. International Lad -- Internationalism B -- v. 380. Internationalism C -- Iowa R -- v. 381. Iowa S -- Irish L -- v. 382. Irish M -- Isa -- v. 383. Isb -- Italian Language H -- v. 384. Italian Language I -- Italy, History to 1815 -- v. 385. Italy, History-After 1815 -- Iz -- v. 386. J -- Jagem -- v. 387. Jagen -- Jansen T -- v. 388. Jansen U -- Jard -- v. 389. Jaré -- Jels -- v. 390. Jelt -- Jesuits and Jesuitism U -- v. 391. Jesuits and Jesuitism V -- Jews, Anti-Semitic Writings M -- v. 392. Jews, Anti-Semitic Writings N -- Jews So -- v. 393. Jews Sp -- Johnm -- v. 394. Johnn -- Jolk -- v. 395. Joll -- Jorg -- v. 396. Jorh -- Journey B -- v. 397. Journey C -- Juk -- v. 398. Jul -- Juvenile Literature, Drama, American C -- v. 399. Juvenile Literature, Drama, American D -- Jz -- v. 400. K -- Kampe -- v. 401. Kampf -- Karo -- v. 402. Karp -- Keem -- v. 403. Keen -- Kennedy J -- v. 404. Kennedy K -- Kets -- v. 405. Kett -- Kinf -- v. 406. King -- Kirr -- v. 407. Kirs -- Kloo -- v. 408. Klop -- Kobd -- v. 409. Kobe -- Kolor -- v. 410. Kolos -- Kor -- v. 411. Kos -- Kreus -- v. 412. Kreut -- Kuer -- v. 413. Kues -- Kz. ; v. 330. H -- Hahm -- v. 331. Hahn -- Hall J -- v. 332. Hall K -- Hamilton J -- v. 333. Hamilton K -- Handwriting R -- v. 334. Handwriting S -- Harbors M -- v. 335. Harbors N -- Harper V -- v. 336. Harper W -- Hartmann K -- v. 337. Hartmann L -- Hathaway E -- v. 338. Hathaway F -- Hawkins L -- v. 339. Hawkins M -- Heart's T -- v. 340. Hearts U -- Hegel H -- v. 341. Hegel I -- Heller J -- v. 342. Heller K -- Henry of K -- v. 343. Henry of L -- Heredity R -- v. 344. Heredity S -- Hertling O -- v. 345. Hertling P -- Hibben S -- v. 346. Hibben T -- Hiller F -- v. 347. Hiller G -- Historia A -- v. 348. Historia B -- History, General-18th Century Works B -- v. 349. History, General-18th Century Works C -- Hodge B -- v. 350. Hodge C -- Hog -- v. 351. Hoh -- Holr -- v. 352. Hols -- Hond -- v. 353. Hone -- Horn L -- v. 354. Horn M -- Hot R -- v. 355. Hot S -- Housing-Working Class H -- v. 356. Housing-Working Class I -- Howl -- v. 357. Howm -- Hughes F -- v. 358. Hughes G -- Humo -- v. 359. Hump -- Hunting N -- v. 360. Hunting O -- Hut -- v. 361. Huu -- Hygiene, Public L -- v. 362. Hygiene, Public M -- Hyz. ; v. 291. G -- Gall L -- v. 292. Gall M -- Gandía E -- v. 293. Gandía F -- Gardiner G -- v. 294. Gardiner H -- Gases A -- v. 295. Gases B -- Gazs -- v. 296. Gazt -- General E -- v. 297. General F -- Geography As -- v. 298. Geography At -- Geology O -- v. 299. Geology P -- Geometry S -- v. 300. Geometry T -- Gerk -- v. 301. Gerl -- German Literature S -- v. 302. German Literature T -- Germany C -- v. 303. Germany D -- Germany-History 1847 -- v. 304. German-History 1848 -- Gerom -- v. 305. Geron -- Giac -- v. 306. Giad -- Gilds G -- v. 307. Gilds H -- Girk -- v. 308. Girl -- Glay -- v. 309. Glaz -- Godf -- v. 310. Godg -- Gold Mines and Mining-Al -- v. 311. Gold Mines and Mining-Am -- Gol [i.e. Golz] -- v. 312. Gom -- Gook -- v. 313. Gool -- Goula -- v. 314. Goulb -- Grad -- v. 315. Grae -- Grang -- v. 316. Granh -- Great Britain I -- v. 317. Great Britain J -- Great Britain-Description and Travel,1800-1850 -- v. 318. Great Britain-Description and Travel, 1850-1900 -- Great Britain-Govt. B -- v. 319. Great Britain-Govt. C -- Great Britain-Hist., 19th cent. F -- v. 320. Great Britain-Hist.,19th cent. G -- Great Britain-Politics, 1660-1714 R -- v. 321. Great Britain-Politics, 1660-1714 S -- Great Britain-Trade, Board of U -- v. 322. Great Britain-Trade, Board of V -- Greece (Modern)-History, 1830 M -- v. 323. Greece (Modern)-History, 1830 N -- Greene H -- v. 324. Greene I -- Grey N -- v. 325. Grey O -- Grog -- v. 326. Groh -- Grunds -- v. 327. Grundt S -- Gueu -- v. 328. Guev -- Gumo -- v. 329. Gump -- Gzow. ; v. 249. F -- Fairs F -- v. 250. Fairs G -- Fans -- v. 251. Fant -- Fascism-Germany B -- v. 252. Fascism-Germany C -- Fearh -- v. 253. Feari -- Felln -- v. 254. Fello -- Ferrari -- v. 255. Ferrarj -- Fev -- v. 256. Few -- Fiction, American Ham -- v. 257. Fiction, American Han -- Fiction, American Will -- v. 258. Fiction, American Wilm -- Fiction, Dutch A -- v. 259. Fiction, Dutch B -- Fiction, English Kim -- v. 260. Fiction, English Kin -- Fiction, Flemish L -- v. 261. Fiction, Flemish M -- Fiction, German A -- v. 262. Fiction, German B -- Fiction, Lettish J -- v. 263. Fiction, Lettish K -- Fiction, Swiss-German B -- v. 264. Fiction, Swiss-German C -- Filmr -- v. 265. Films -- Finance, U.S., 1813 -- v. 266. Finance, U.S., 1814 -- Finland R -- v. 267. Finland S -- Fischa -- v. 268. Fischb -- Fishing A -- v. 269. Fishing B -- Flanders G -- v. 270. Flanders H -- Flora F -- v. 271. Flora G -- Flya -- v. 272. Flyb -- Folklore N -- v. 273. Folklore O -- Fond -- v. 274. Fone -- Før N -- v. 275. For O -- Forestry-Germany S -- v. 276. Forestry-Germany T -- Forter -- v. 277. Fortes -- Fourm -- v. 278. Fourn -- France Ar -- v. 279. France As -- France-Foreign Relations R -- v. 280. France-Foreign Relations S -- France-History-Revolution O -- v. 281. France-History-Revolution P -- France-Statistics M -- v. 282. France-Statistics N -- Frank E -- v. 283. Frank F -- Frederick I, King of Prussia -- v. 284. Frederick II, King of Prussia -- Freemasons P -- v. 285. Freemasons Q -- French Language-Dictionaries D -- v. 286. French Language-Dictionaries E -- Fresco Paintings B -- v. 287. Fresco Paintings C -- Friends, Society of. L -- v. 288. Friends, Society of. M -- Früh [i.e. Fruh] -- v. 289. Frui -- Funck J -- v. 290. Funck K -- Fyz. ; v. 214. E -- Eastern Col -- v. 215. Eastern Com -- Ecole B -- v. 216. Ecole C -- Economic History-Chile F -- v. 217. Economic History-Chile G -- Economic History I -- v. 218. Economic History J -- Economic History-U.S.F -- v. 219. Economic History-U.S.G -- Economics, 1848-1889 E -- v. 220. Economics, 1848-1889 F -- Edel -- v. 221. Edem -- Education E -- v. 222. Education F -- Education O -- v. 223. Education P -- Education-U.S.-N.J.T -- v. 224. Education-U.S.-N.J.U -- Egypt C -- v. 225. Egypt D -- Eisenstein I -- v. 226. Eisenstein J -- Electric M -- v. 227. Electric N -- Electrons B -- v. 228. Electrons C -- Ellis S -- v. 229. Ellis T -- Emigration, Canada N -- v. 230. Emigration, Canada O -- Enchanted R -- v. 231. Enchanted S -- Engineering Ch -- v. 232. Engineering Ci -- English Language-Dictionaries G -- v. 233. English Language-Dictionaries H -- English Literature S -- v. 234. English Literature T -- Epitaphs T -- v. 235. Epitaphs U -- Ero -- v. 236. Erp -- Espl -- v. 237. Espm -- Essays P -- v. 238. Essays R -- Ethics G -- v. 239. Ethics H -- Etr -- v. 240. Ets -- Europe-History H -- v. 241. Europe-History I -- European War, Aerial Operations M -- v. 242. European War, Aerial Operations N -- European War, Economic Aspects Germany K -- v. 243. European War, Economic Aspects Germany L -- European War, Neutrality R -- v. 244. European War, Neutrality S -- European War, Regimental History F -- v. 245. European War, Regimental History G -- European War, Great Britain G -- v. 246. European War, Great Britain H -- Evero -- v. 247. Everp -- Exhibitions C -- v. 248. Exhibitions D -- Ez. ; v. 177. D -- Dale C -- v. 178. Dale D -- Dancing F -- v. 179. Dancing G -- Danzig G -- v. 180. Danzig H -- Dauw -- v. 181. Daux -- Dawn -- v. 182. Dawo -- Debray -- v. 183. Debraz -- Defei -- v. 184. Defel -- Delaware C -- v. 185. Delaware D -- Democracy-U.S.B -- v. 186. Democracy-U.S.C -- Denton, Name [i.e. Denton (Name)] -- v. 187. Denton, County [i.e. Denton County] -- Desmares -- v. 188. Desmaret -- Deutsche J -- v. 189. Deutsche K -- Dewar M -- v. 190. Dewar N -- Dickens, Charles F -- v. 191. Dickens, Charles G -- Dikes H -- v. 192. Dikes I -- Disaster Relief B -- v. 193. Disaster Relief C -- Divo -- v. 194. Divr -- Dog L -- v. 195. Dog M -- Donato L -- v. 196. Donato M -- Douglas P -- v. 197. Douglas R -- Drama, American A -- v. 198. Drama, American B -- Drama, American Mi -- v. 199. Drama, American Mo -- Drama C -- v. 200. Drama D -- Drama, English Hol -- v. 201. Drama, English Hom -- Drama, English Translations From . R -- v. 202. Drama, English Translations From . S -- Drama, French J -- v. 203. Drama, French K -- Drama, German Bas -- v. 204. Drama, German Bat -- Drama, German, Low German D -- v. 205. Drama, German, Low German E -- Drama, L -- v. 206. Drama, M -- Drama, Spanish Ger -- v. 207. Drama, Spanish Ges -- Drama, Walloon W -- v. 208. Drama, Walloon X -- Dreu -- v. 209. Drev -- Dublin U -- v. 210. Dublin V -- Duke O -- v. 211. Duke P -- Duper -- v. 212. Dupes -- Dutch Language D -- v. 213. Dutch Language E -- Dz. ; v. 107. C -- Cah -- v. 108. Cai -- Cale -- v. 109. Calf -- California V -- v. 110. California W -- Cameron, I -- v. 111. Cameron, J -- Canada B -- v. 112. Canada C -- Canada Statistics Bureau M -- v. 113. Canada Statistics Bureau N -- Canaq -- v. 114. Canar -- Capeh -- v. 115. Capei -- Cardif -- v. 116. Cardig -- Carm -- v. 117. Carn -- Carrik -- v. 118. Carril -- Case A -- v. 119. Case B -- Castles R -- v. 120. Castles S -- Cathedrals S -- v. 121. Cathedrals T -- Catholic Church Roman L -- v. 122. Catholic Church Roman M -- Cauch -- v. 123. Cauci -- Cement and Concrete M -- v. 124. Cement and Concrete P -- Ceo -- v. 125. Cep -- Chah -- v. 126. Chai -- Chand -- v. 127. Chane -- Charities I -- v. 128. Charities J -- Charz -- v. 129. Chas -- Chemical Industries I -- v. 130. Chemical Industries J -- Chemm -- v. 131. Chemn -- Chicago B -- v. 132. Chicago C -- Children AC -- v. 133. Children AD -- Chile T -- v. 134. Chile U -- Chinese A -- v. 135. Chinese B -- Christ L -- v. 136. Christ M -- Christianity E -- v. 137. Christianity F -- Church Al -- v. 138. Church Am -- Church I -- v. 139. Church J -- Chyz -- v. 140. Ci -- Cities-Plans-D -- v. 141. Cities-Plans-E -- Civil R -- v. 142. Civil S -- Claq -- v. 143. Clar -- Classification K -- v. 144. Classification L -- Clergy F -- v. 145. Clergy G -- Club T -- v. 146. Club U -- Cobb -- v. 147. Cobd -- Coi -- v. 148. Coj -- Collection K -- v. 149. Collection L -- Collim -- v. 150. Collin -- Colonies and Colonization A -- v. 151. Colonies and Colonization B -- Columbia University Q -- v. 152. Columbia University R -- Coml -- v. 153. Comm -- Commerce Am -- v. 154. Commerce An -- Commerce-New York -- v. 155. Commerce-New Zealand -- Commis -- v. 156. Commit -- Competition-Unfair F -- v. 157. Competition-Unfair G -- Cone -- v. 158. Conf -- Congres H -- v. 159. Congres I -- Conr -- v. 160. Cons -- Continuation L -- v. 161. Continuation M -- Cookery B -- v. 162. Cookery C -- Cooperation S -- v. 163. Cooperation T -- Copyright M -- v. 164. Copyright N -- Coronations G -- v. 165. Coronations H -- Cortazar C -- v. 166. Cortazar D -- Cotner T -- v. 167. Cotner U -- Country Life-United States -- v. 168. Country Life-Uruguay -- Cowper W -- v. 169. Cowper Family -- Creation-Biblical Account-H -- v. 170. Creation-Biblical Account-I -- Criminal H -- v. 171. Criminal I -- Crip -- v. 172. Criq -- Crosby G -- v. 173. Crosby H -- Cua -- v. 174. Cub -- Cunningham A -- v. 175. Cunningham B -- Cux -- v. 176. Cuy -- Cz. ; v. 52. B -- Bader -- v. 53. Bades -- Baker, I -- v. 54. Baker, J -- Ballads, E -- v. 55. Ballads, F -- Banco P -- v. 56. Banco R -- Banks and Banking-Gt. Br. S -- v. 57. Banks and Banking-Gt. Br. T -- Baptists-U -- v. 58. Baptists-V -- Barlac -- v. 59. Barlad -- Barry, I -- v. 60. Barry, J -- Basr -- v. 61. Bass -- Baud -- v. 62. Baue -- Beac -- v. 63. Bead -- Beck -- v. 64. Becl -- Beh -- v. 65. Bei -- Belk -- v. 66. Bell -- Bend -- v. 67. Bene -- Benz -- v. 68. Beo -- Berlin F -- v. 69. Berlin G -- Berr -- v. 70. Bers -- Bet -- v. 71. Beu -- Bible. Zulu -- v. 72. Bible. Selections -- Bible. N.T.: Crit -- v. 73. Bible. N.T.-D -- Bible. O.T. Pr -- v. 74. Bible. O.T. Ps -- Bibliography-O -- v. 75. Bibliography-P -- Bibliotheca O -- v. 76. Bibliotheca P -- Bik -- v. 77. Bil -- Bio -- v. 78. Bip -- Bisl -- v. 79. Bism -- Blai -- v. 80. Blaj -- Blis -- v. 81. Blit -- Bob -- v. 82. Boc -- Bog -- v. 83. Boh -- Bolr -- v. 84. Bols -- Bolz -- v. 85. Bom -- Bon -- v. 86. Boo -- Bool -- v. 87. Boom -- Bor -- v. 88. Bos -- Botany-R -- v. 89. Botany-S -- Bouq -- v. 90. Bour -- Boyd -- v. 91. Boye -- Bram -- v. 92. Bran -- Brazil D -- v. 93. Brazil E -- Brer -- v. 94. Bres -- Brid -- v. 95. Brie -- British E -- v. 96. British F -- Brom -- v. 97. Bron -- Brov -- v. 98. Brow -- Brt -- v. 99. Bru -- Bryc -- v. 100. Bryd -- Budget-E -- v. 101. Budget F -- Building C -- v. 102. Building D -- Bulle -- v. 103. Bullf -- Burgf -- v. 104. Burgg -- Burrow, M -- v. 105. Burrow, N -- Buss -- v. 106. Bust -- Bz. ; v. 1. A -- Aben -- v. 2. Abeo -- Académie de F -- v. 3. Académie du G -- Achm -- v. 4. Achn -- Adams, D -- v. 5. Adams, E -- Ador -- v. 6. Adós -- Aeronautics-Ac -- v. 7. Aeronautics-Ad -- Aesoph -- v. 8. Aesopi -- Africa, So -- v. 9. Africa, Sp -- Agar -- v. 10. Agas -- Agriculture-Economics-F -- v. 11. Agriculture-Economics-G -- Agriculture-C [i.e. Agriculture (Place) C] -- v. 12. Agriculture-D [i.e. Agriculture (Place) D] -- Air-E -- v. 13. Air-F -- Alabam -- v. 14. Alaban -- Alcaraz, Em -- v. 15. Alcaraz, En -- Alexan, F -- v. 16. Alexan, G -- Aliens-H -- v. 17. Aliens-I -- Allied J -- v. 18. Allied K -- Alphabet, S -- v. 19. Alphabet, T -- Alz -- v. 20. Am -- America M -- v. 21. America-N -- American Fab -- v. 22. American Fac -- American Languages-Q -- v. 23. American Languages-R -- American Pio -- v. 24. American Pip -- Americans in L -- v. 25. Americans in M -- Amy -- v. 26. Amz -- Anderson, S -- v. 27. Anderson T -- Angle S -- v. 28. Angle T -- Annal -- v. 29. Annam -- Anthon -- v. 30. Anthoo -- Apar -- v. 31. Apas -- Aqueb -- v. 32. Aquec -- Arauco, C -- v. 33. Arauco D -- Architectural D -- v. 34. Architectural E -- Architecture, Ecclesiastical-F -- v. 35. Architecture, Ecclesiastical-G -- Arens -- v. 36. Arent -- Aristoc -- v. 37. Aristod -- Armitage, R -- v. 38. Armitage, S -- Army, R -- v. 39. Army, S -- Arres -- v. 40. Arret -- Art-Essays and Misc. G -- v. 41. Art-Essays and Misc. H -- Art Per [i.e. Art Pers]-- v. 42. Art, Peru -- Arz -- v. 43. As -- Assat -- v. 44. Assau -- Assz -- v. 45. Ast -- Athenaeum I -- v. 46. Athenaeum L -- Attention M -- v. 47. Attention N -- Auq -- v. 48. Aurauco D -- Austria B -- v. 49. Austria-C -- Authorship T -- v. 50. Authorship U -- Auy -- v. 51. Auz -- Az. ; Mode of access: Internet.
